“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already demonstrated scientifically that our process and product is exceptional. This study will enhance our...

POMPANO BEACH, FLORIDA, September 26, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today  the approval of an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of Vendaje in diabetic patients suffering from foot ulcers. “This is a landmark study for...

Leading wound market solutions provider will lead BioStem’s commercialization of AmnioWrap2™ AmnioWrap2 is a versatile allograft solution for wound applications POMPANO BEACH, FLORIDA, September 19, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placenta-derived biologics for advanced wound care, has entered an agreement with leading US wound market solutions provider, Venture Medical,...

POMPANO BEACH, FLORIDA, September 18, 2023 - BioStem Technologies Inc. (OTC: BSEM), an innovator in the development, manufacture, and commercialization of allografts for regenerative therapies, has engaged PCG Advisory, Inc., a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications. PCG Advisory will work closely with BioStem’s senior management team to build upon the company’s investor relations outreach and deliver a...